链接全球制药生态 共筑健康未来

Connecting the Global Pharmaceutical

Ecosystem, Building a Healthier Future Together

海南中和药业闪耀 2025 德国法兰克福 CPHI 原料药展

Hainan Zhonghe Pharmaceutical Shines at CPHI Frankfurt 2025

2025年10月28日至30日，全球制药行业的年度盛会 —— 世界制药原料展览会（CPHI Frankfurt 2025）在德国法兰克福展览中心盛大落幕。作为全球规模最大、影响力最广的制药专业展会，本届盛会汇聚了来自 150 多个国家和地区的 2500 余家参展商及 45000 余名专业观众，成为洞察行业趋势、链接全球资源的核心枢纽。

From October 28 to 30, 2025, the world’s leading pharmaceutical event — CPHI Frankfurt 2025 — successfully concluded at Messe Frankfurt, Germany. As the largest and most influential pharmaceutical exhibition globally, this year’s event brought together over 2,500 exhibitors and 45,000 professional visitors from more than 150 countries and regions, serving as a central hub for industry insights and global collaboration.

作为中国多肽药物研发与生产的领军企业，海南中和药业股份有限公司（以下简称“海南中和药业”）携其领先的多肽产品线及国际化服务方案盛装出席，与全球业界伙伴进行了深度交流，充分展示了其在多肽领域的生产能力与国际化战略布局。

As a leading enterprise in peptide drug research, development, and manufacturing in China, Hainan Zhonghe Pharmaceutical Co., Ltd. made a grand appearance at the event, showcasing its cutting-edge peptide product portfolio and comprehensive international service solutions. The company engaged in in-depth exchanges with global industry partners, fully demonstrating its strong manufacturing capabilities and strategic international presence in the peptide field.

● 聚焦核心优势，展示多肽技术硬核实力

● Highlighting Core Strengths, Showcasing the Power of Peptide Innovation

本次展会，海南中和药业重点展示了公司在免疫、肿瘤、肝病、急救、消化、泌尿、妇科围产等领域的核心原料药产品矩阵，以及原料制剂一体化的产业优势。公司凭借其在固相合成技术上的深厚积累，向国际客户呈现了从克级到公斤级、从常规到复杂长链多肽的稳定、规模化生产能力。

At this exhibition, Hainan Zhonghe Pharmaceutical focused on showcasing its core API product portfolio across key therapeutic areas including immunology, oncology, hepatology, emergency medicine, gastroenterology, urology, and obstetrics & gynecology, as well as its integrated advantages in both API and finished dosage manufacturing. Leveraging its deep expertise in solid-phase synthesis technology, the company demonstrated to international clients its stable and scalable production capabilities, ranging from gram to kilogram levels and covering both conventional and complex long-chain peptides.

展会期间，海南中和药业的展台吸引了大量专业访客驻足咨询与洽谈，我们通过产品展板、技术手册、现场答疑等多种形式全方面推广我们的核心成果。公司的商务团队和技术专家与全球各地区的潜在客户、合作伙伴就多肽药物的研发趋势、质量管控、产能保障和法规事务等议题进行了广泛而深入的探讨，并达成了多项初步合作意向。

During the exhibition, Hainan Zhonghe Pharmaceutical’s booth attracted a large number of professional visitors for consultations and business discussions. Through product displays, technical brochures, and on-site Q&A sessions, the company comprehensively showcased its core achievements and technological strengths. The business and technical teams engaged in extensive and in-depth exchanges with potential clients and partners from around the world on topics such as peptide drug R&D trends, quality management, production capacity assurance, and regulatory affairs, leading to the establishment of multiple preliminary cooperation intentions.

● 深化国际合作，共拓全球医药市场

● Forging International Collaborations to Explore Global Pharma Horizons

CPHI是全球制药原料领域最重要的交流平台。通过此次参展，我们不仅巩固了与老客户的信任关系，更结识了众多志同道合的新伙伴。我们深切感受到全球市场对高质量、高性价比多肽药物日益增长的需求。海南中和药业将始终坚持 “立足中国、服务全球” 的发展理念，持续完善产业链布局，强化研发创新投入，推动产品与服务向更高质量、更宽领域、更深层次发展。

CPHI is the world’s most important platform for exchanges in the pharmaceutical API sector. Through our participation in this year’s exhibition, we not only strengthened trust with existing clients but also connected with many like-minded new partners. We deeply felt the growing global demand for high-quality, cost-effective peptide drugs. Hainan Zhonghe Pharmaceutical will continue to uphold its development philosophy of “Rooted in China, Serving the World”, steadily optimizing its industrial chain layout, enhancing investment in R&D and innovation, and promoting its products and services toward higher quality, broader scope, and deeper impact.

此次法兰克福之行，是海南中和药业推进国际化战略的关键一步。通过面对面的交流，公司进一步了解了国际市场的动态与需求，也为未来拓展更广阔的海外市场奠定了坚实的基础。

This trip to Frankfurt marked a key step in Hainan Zhonghe Pharmaceutical’s internationalization strategy. Through face-to-face exchanges, the company gained a deeper understanding of international market dynamics and needs, laying a solid foundation for expanding its presence in global markets.

关于海南中和药业股份有限公司

About Hainan Zhonghe Pharmaceutical Co., Ltd.

海南中和药业股份有限公司（以下简称中和药业）成立于1995年4月17日，是我国专业从事化学合成多肽药物的研究和实现产业化的国家高新技术企业，中国国内化学合成多肽类新药“注射用胸腺五肽”就由中和药业自行研发上市，并在2003年“非典”疫情中发挥了重大作用，被海南省人民政府予以嘉奖。历经近30年的发展，公司产品已涵盖免疫、肿瘤、肝病、心血管、内分泌、妇科围产等多个治疗领域，并拥有多肽原料药、化学原料药及小容量注射剂（包括预灌封、卡式瓶）、冻干粉针剂、片剂、胶囊剂等多种剂型的生产能力，产品已成功出口韩国、乌兹别克斯坦、蒙古、巴基斯坦等多个国家和地区。

Hainan Zhonghe Pharmaceutical Co., Ltd. (hereinafter Zhonghe Pharmaceutical) was founded on April 17, 1995, and is a national high-tech enterprise in China specializing in the research and industrialization of chemically synthesized peptide drugs. The company independently developed and launched China’s first chemically synthesized peptide new drug, Thymopentin for Injection, which played a significant role during the SARS outbreak in 2003 and was recognized with an award by the Hainan Provincial Government. After nearly 30 years of development, Zhonghe Pharmaceutical’s products now cover multiple therapeutic areas, including immunology, oncology, hepatology, cardiovascular, endocrinology, and obstetrics & gynecology. The company has production capabilities for peptide APIs, chemical APIs, and various dosage forms, including small-volume injections (pre-filled and cartridge vials), lyophilized powders for injection, tablets, and capsules. Its products have been successfully exported to South Korea, Uzbekistan, Mongolia, Pakistan, and other countries and regions.

欢迎扫描二维码，浏览我们的药品、原料药及化妆品产品目录。

Scan the QR code to discover our range of pharmaceuticals, APIs, and cosmetics

孙经理 Director Sun:18078993802(国内) Domestic Department

唐经理 Director Tang:13876688684(国内) Domestic Department

TEL:0898-66802207(国际) International Department                    

E-mail: lizhongjing@zhonghe.cn(国际) International Department